ArshadSKilgorePChaudhryZS, et al.Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. Int J Infect Dis.2020;97:394–403. doi:10.1016/j.ijid.2020.06.099
2.
DochertyABHarrisonEMGreenCA, et al.Features of 20 133 UK patients in hospital with Covid-19 using the ISARIC WHO clinical characterisation protocol: prospective observational cohort study. BMJ. 2020;369:1–12. doi:10.1136/bmj.m1985
3.
WilsonKCChotirmallSHBaiCRelloJ. COVID-19: interim guidance on management pending empirical evidence. American Thoracic Society. Published April 3, 2020. Accessed April 4, 2020. https://www.thoracic.org/covid/covid-19-guidance.pdf
World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected interim guidance. WHO. Published May 27, 2020. Accessed April 7, 2020. https://www.who.int/publications/i/item/clinical-management-of-covid-19
6.
VillarJMarcoCPastoresSMeduriGU. Rationale for prolonged corticosteroid treatment in the acute respiratory distress syndrome caused by coronavirus disease 2019. Crit Care Explor. 2020;2(4):e0111. doi:10.1097/CCE.0000000000000111
7.
KanneJPLittleBPChungJHElickerBMKetaiLH. Essentials for radiologists on COVID-19: an update—Radiology Scientific Expert Panel. Radiology. 2020;296(2):E113–E114. doi:10.1148/radiol.2020200527
8.
KoryPKanneJP. CoV-2 organising pneumonia: “has there been a widespread failure to identify and treat this prevalent condition in COVID-19?”BMJ Open Resp Res. 2020;7(1):1–4. doi:10.1136/bmjresp-2020-000724
9.
RichardsonSHirschJSNarasimhanM, et al.Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020;323(20):2052–2059. doi:10.1001/jama.2020.6775.
10.
ZhouFYuTDuR, et al.Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet.2020;394(10229):1054–1062doi:10.1016/S0140-6736(20)30566-3
11.
HorbyPLimWSEmbersonJ, et al.Dexamethasone in hospitalized patients with Covid-19—preliminary report[published online ahead of print July 17, 2020]. 2020. NEJM. doi:10.1056/NEJMoa2021436
12.
NadkarniGNLalaABagiellaE, et al.Anticoagulation, mortality, bleeding and pathology among patients hospitalized with COVID-19: a single health system study. 2020. JACC. doi:10.1016/j.jacc.2020.08.041
13.
ZhangXJQinJJChengX, et al.Clinical and translational report in-hospital use of statins is associated with a reduced risk of mortality among individuals with in-hospital use of statins is associated with a reduced risk of mortality among individuals with COVID-19. Cell Metab. 2020;32(2):176–187. doi:10.1016/j.cmet.2020.06et .015
14.
CastilloMEEntrenas CostaLMVaquero BarriosJM, et al.Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: a pilot randomized clinical study. J Steroid Biochem Mol Biol.2020;203:105751. doi:10.1016/j.jsbmb.2020.105751
15.
ZhangJRaoXLiY, et al.High-dose vitamin C infusion for the treatment of critically ill COVID-19[published online August 10, 2020]. Res Square. 2020. doi:10.21203/rs.3.rs-52778/v1
16.
JehiLJiXMilinovichA, et al.Individualizing risk prediction for positive COVID-19 testing: results from 11,672 patients. Chest.2020;158(4):1364–1375. doi:10.1016/j.chest.2020.05.580
17.
NicastriEBartoliTALeporeLPalmieriFMarchioniLIppolitoG. National Institute for the Infectious Diseases “L. spallanzani”, IRCCS. Recommendations for COVID-19 clinical management. Infect Dis Rep. 2020;12(1):8543. doi:10.4081/idr.2020
18.
YeZRochwergBWangY, et al.Treatment of patients with nonsevere and severe coronavirus disease 2019: an evidence based guideline. CMAJ. 2020;192(20):536–545. doi:10.1503/cmaj.200648
Yale New-Haven Hospital System. Initial treatment algorithm for hospitalized adults with severe COVID-19 respiratory failure, including mechanical ventilation and ECMO PLUS confirmed POSITIVE SARS-CoV- 2 by PCR. Yale New-Haven Hospital System. Published April 1, 2020. Accessed April 10, 2020. https://medicine.yale.edu/news-article/23611/
21.
China National Health Commission. Chinese Clinical Guidance for Covid-19 Pneumonia (7th Edition) 2020. China National Health Commission. Published March 16, 2020. Accessed November 11, 2020. http://kjfy.meetingchina.org/msite/news/show/cn/3337.html
22.
WatererGWRelloJWunderinkRG. COVID-19: first do no harm. Am J Respir Crit Care Med. 2020;201(11):1324–1325. doi:10.1164/rccm.202004-1153ED
23.
VillarJConfalonieriMPastoresSMMeduriGU. Rationale for prolonged corticosteroid treatment in the acute respiratory distress syndrome caused by coronavirus disease 2019. Crit Care Explor. 2020;2(4):e0111doi:10.1097/CCE.0000000000000111
24.
MeduriGUAnnaneDChrousosGPMarikPESinclairSE. Activation and regulation of systemic inflammation in ARDS: rationale for prolonged glucocorticoid therapy. Chest. 2009;136(6):1631–1643. doi:10.1378/chest.08-2408
25.
ParkJHLeeHK. Re-analysis of single cell transcriptome reveals that the NR3C1-CXCL8-neutrophil axis determines the severity of COVID-19. Front Immunol. 2020;11(August):1–9. doi:10.3389/fimmu.2020.02145
XuZShiLWangY, et al.Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420–422. doi:10.1016/S2213-2600(20)30076-X
29.
ChenRCTangXPTanSY, et al.Treatment of severe acute respiratory syndrome with glucosteroids: the Guangzhou experience. Chest. 2006;129(6):1441–1452. doi:10.1378/chest.129.6.1441
30.
Yin-Chun YamLChun-Wing LauAYuk-Lin LaiFShungEChanJWongV. Corticosteroid treatment of severe acute respiratory syndrome in Hong Kong. J Infect. 2007;54(1):28–39. doi:10.1016/j.jinf.2006.01.005
31.
LongYXuYWangB, et al.Clinical recommendations from an observational study on MERS: glucocorticoids was benefit in treating SARS patients. Int J Clin Exp Med. 2016;9(5):8865–8873.
32.
LiHYangSGGuL, et al.Effect of low-to-moderate-dose corticosteroids on mortality of hospitalized adolescents and adults with influenza A(H1N1)pdm09 viral pneumonia. Influenza Other Respi Viruses. 2017;11(4):345–354. doi:10.1111/irv.12456
33.
WuCChenXCaiY, et al.Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med.2020;180(7):934–943.
34.
FadelRMorrisonARVahiaA, et al.Early short course corticosteroids in hospitalized patients with COVID-19[published online ahead of print May 19, 2020]. Clin Infect Dis. 2020. doi:10.1093/cid/ciaa601
35.
Fernández CruzARuiz-AntoránBMuñoz GómezA, et al.Impact of glucocorticoid treatment in SARS-CoV-2 infection mortality: a retrospective controlled cohort study[published online June 22, 2020]. Antimicrob Agents Chemother. 2020. doi:10.1128/aac.01168-20
36.
MeduriGUBridgesLShihMCMarikPESiemieniukRACKocakM. Prolonged glucocorticoid treatment is associated with improved ARDS outcomes: analysis of individual patients’ data from four randomized trials and trial-level meta-analysis of the updated literature. Intensive Care Med. 2016;42(5):829–840. doi:10.1007/s00134-015-4095-4
37.
PastoresSMAnnaneDRochwergB.Guidelines for the diagnosis and management of critical illness-related corticosteroid insufficiency (CIRCI) in critically ill patients (Part II): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017. Intensive Care Med. 2018;44(4):474–477doi:10.1007/s00134-017-4951-55
38.
GreosLSVichyanondPBloedowDC, et al.Methylprednisolone achieves greater concentrations in the lung than prednisolone: a pharmacokinetic analysis. Am Rev Respir Dis. 1991;144(3):586–592.doi:10.1164/ajrccm/144.3_pt_1.586
39.
LiSMGMillerDDYatesCR. Evaluation of AP-1 and NF-kB inhibitory potency for oral glucocorticoids. Am Rev of Respir Dis. 2003:5(S1):R6173.
40.
MeduriGUTolleyEAChrousosGPStentzF. Prolonged methylprednisolone treatment suppresses systemic inflammation in patients with unresolving acute respiratory distress syndrome. Am J Respir Crit Care Med. 2002;165(7):983–991. doi:10.1164/ajrccm.165.7.2106014
41.
DraghiciSNguyenTMSonnaLA, et al.COVID-19: disease pathways and gene expression changes predict methylprednisolone can improve outcome in severe cases[published online May 19, 2020]. Medrxiv. doi:10.1101/2020.05.06.20076687
42.
ArabiYMMandourahYAl-HameedF, et al.Corticosteroid therapy for critically ill patients with Middle East Respiratory Syndrome. Am J Respir Crit Care Med. 2018;197(6):757–767doi:10.1164/rccm.201706-1172OC
43.
SaltonFConfalonieriPSantusP, et al.Prolonged low-dose methylprednisolone in patients with severe COVID-19 pneumonia. Medrxiv. 2020;7(10):ofaa421. doi:10.1101/2020.06.17.20134031
44.
CorralLBahamondeARevillasFA, et al.GLUCOCOVID: A controlled trial of methylprednisolone in adults hospitalized with COVID-19 pneumonia[published online June 18, 2020]. 2020. Medrxiv. doi:10.1101/2020.06.17.20133579.
45.
World Health Organization Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA. 2020;324(13):1330–1341. doi:10.1001/jama.2020.17023
MarikPEKhangooraVRiveraRHooperMHCatravasJ. Hydrocortisone, vitamin C, and thiamine for the treatment of severe sepsis and septic shock: a retrospective before-after study. Chest. 2017;151(6):1229–1238. doi:10.1016/j.chest.2016.11.036
48.
TanakaHMatsudaTMiyagantaniYYukiokaTMatsudaHShimazakiS. Reduction of resuscitation fluid volumes in severely burned patients using ascorbic acid administration: a randomized, prospective study. Arch Surg. 2000;135(3):326–331. doi:10.1001/archsurg.135.3.326
49.
MoskowitzAAndersenLWHuangDT, et al.Ascorbic acid, corticosteroids, and thiamine in sepsis: a review of the biologic rationale and the present state of clinical evaluation. Crit Care. 2018;22(1):283. doi:10.1186/s13054-018-2217-4
50.
ZhangMJativaDF. Vitamin C supplementation in the critically ill: a systematic review and meta-analysis. SAGE Open Med. 2018;6. doi:10.1177/2050312118807615
51.
Blanco-MeloDNilsson-PayantBELiuWC, et al.Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell. 2020;181(5):1036–1045. doi:10.1016/j.cell.2020.04.026
52.
QinCZhouLHuZ, et al.Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis. 2020;71(15):762–768. doi:10.1093/cid/ciaa248.
53.
AcharyaDLiuGQGackMU. Dysregulation of type I interferon responses in COVID-19. Nat Rev Immunol. 2020;20(7):387–398. doi:10.1038/s41577-020-0346-x
54.
KimYKimHBaeS, et al.Vitamin C is an essential factor on the anti-viral immune responses through the production of interferon-α/β at the initial stage of influenza A virus (H3N2) infection. Immune Netw. 2013;13(2):70–74doi:10.4110/in.2013.13.2.70
55.
CaiYLiYFTangLP, et al.A new mechanism of vitamin C effects on A/FM/1/47(H1N1) virus-induced pneumonia in restraint-stressed mice. Biomed Res Int. 2015;2015:1–12. doi:10.1155/2015/675149
56.
ChatterjeeIBMajumderAKNandiBKSubramanianN. Synthesis and some major functions of vitamin C in animals. Ann N Y Acad Sci. 1975;258(1):24–47. doi:10.1111/j.1749-6632.1975.tb29266.x
57.
WilsonJX. Mechanism of action of vitamin C in sepsis: ascorbate modulates redox signaling in endothelium. BioFactors. 2009;35(1):5–13. doi:10.1002/biof.7
58.
OkamotoKTanakaHMakinoYMakinoI.Restoration of the glucocorticoid receptor function by the phosphodiester compound of vitamins C and E, EPC-K1 (L-ascorbic acid 2-[3,4-dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-2H-1-benzopyran-6-yl hydrogen phosphate] potassium salt), via a redox-dependent mechanism. Biochem Pharmacol. 1998;56(1):79–86. doi:10.1016/S0006-2952(98)00121-X
59.
MarikPE. Vitamin C for the treatment of sepsis: the scientific rationale. Pharmacol Ther. 2018;189:63–70doi:10.1016/j.pharmthera.2018.04.007
60.
CarrACShawGMFowlerAANatarajanR. Ascorbate-dependent vasopressor synthesis: a rationale for vitamin C administration in severe sepsis and septic shock?Crit Care. 2015;19(1):1–8. doi:10.1186/s13054-015-1131-2
61.
TymlK. Vitamin C and microvascular dysfunction in systemic inflammation. Antioxidants. 2017;6(3):49. doi:10.3390/antiox6030049
62.
FowlerAASyedAAKnowlsonS, et al.Phase I safety trial of intravenous ascorbic acid in patients with severe sepsis. J Transl Med. 2014;12(1):32. doi:10.1186/1479-5876-12-32
63.
IglesiasJVassalloAVPatelVVSullivanJBCavanaughJElbagaY. Outcomes of metabolic resuscitation using ascorbic acid, thiamine, and glucocorticoids in the early treatment of sepsis: the ORANGES trial. Chest. 2020;158(1):164–173. doi:10.1016/j.chest.2020.02.049
64.
FowlerAATruwitJDHiteRD, et al.Effect of vitamin C infusion on organ failure and biomarkers of inflammation and vascular injury in patients with sepsis and severe acute respiratory failure: the CITRIS-ALI randomized clinical trial. JAMA. 2019;322(13):1261–1270. doi:10.1001/jama.2019.11825
65.
De GroothHJElbersPWGVincentJL. Vitamin C for sepsis and acute respiratory failure. JAMA. 2020323(8):792. doi:10.1001/jama.2019.21981
66.
HemiläHChalkerE. Vitamin C may reduce the duration of mechanical ventilation in critically ill patients: a meta-regression analysis. J Intensive Care. 2020;8:15. doi:10.1186/s40560-020-0432-y
67.
CollieJTBGreavesRFJonesOAHLamQEastwoodGMBellomoR. Vitamin B1 in critically ill patients: needs and challenges. Clin Chem Lab Med. 2017;55(11):1652–1658. doi:10.1515/cclm-2017-0054
68.
MenezesRRGodinAMRodriguesFF, et al.Thiamine and riboflavin inhibit production of cytokines and increase the anti-inflammatory activity of a corticosteroid in a chronic model of inflammation induced by complete Freund’s adjuvant. Pharmacol Rep. 2017;69(5):1036–1043doi:10.1016/j.pharep.2017.04.011
69.
DonninoMWCarneyECocchiMN, et al.Thiamine deficiency in critically ill patients with sepsis. J Crit Care. 2010;25(4):576–581. doi:10.1016/j.jcrc.2010.03.003
70.
CostaNAGutALde Souza DornaM, et al.Serum thiamine concentration and oxidative stress as predictors of mortality in patients with septic shock. J Crit Care. 2014;29(2):249–252. doi:10.1016/j.jcrc.2013.12.004
71.
CorcoranTBO’NeillMAWebbSARHoKM. Prevalence of vitamin deficiencies on admission: relationship to hospital mortality in critically ill patients. Anaesth Intensive Care. 2009;37(2):254–260. doi:10.1177/0310057x0903700215
72.
DonninoMWAndersenLWChaseM, et al.Randomized, double-blind, placebo-controlled trial of thiamine as a metabolic resuscitator in septic shock: a pilot study. Crit Care Med. 2016;44(2):360–367doi:10.1097/CCM.0000000000001572
73.
WoolumJAAbnerELKellyABastinMLTMorrisPEFlanneryAH. Effect of thiamine administration on lactate clearance and mortality in patients with septic shock. Crit Care Med. 2018;46(11):1747–1752. doi:10.1097/CCM.0000000000003311
74.
MoslemiRKhaliliHMohammadiMMehrabiZMohebbiN. Thiamine for prevention of postoperative delirium in patients undergoing gastrointestinal surgery: a randomized clinical trial. J Res Pharm Pract. 2020;9(1):30–35. doi:10.4103/jrpp.jrpp_19_124
75.
De BiasiSMeschiariMGibelliniL, et al.Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia. Nat Commun. 2020;11(1):1–7. doi:10.1038/s41467-020-17292-4
76.
VatsalyaVLiFFrimodigJ, et al.Therapeutic prospects for TH-17 cell immune storm syndrome and neurological symptoms in COVID-19: thiamine efficacy and safety, in-vitro evidence and pharmacokinetic profile [published online August 25, 2020]. Medxriv. 2020. doi:10.1101/2020.08.23.20177501
77.
ConnorsJMLevyJH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020;135(23):2033–2040. doi:10.1182/blood.2020006000
78.
CuiSChenSLiXLiuSWangF. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020;18(6):1421–1424. doi:10.1111/jth.14830
79.
DanziGBLoffiMGaleazziGGherbesiE. Acute pulmonary embolism and COVID-19 pneumonia: a random association?Eur Heart J. 2020;41(19):1858. doi:10.1093/eurheartj/ehaa254
80.
SaddCRoweTNazeefMKoryPSultanSFaustH. Thromboelastography to detect hypercoagulability and reduced fibrinolysis in coronavirus disease 2019 acute respiratory distress syndrome patients. Crit Care Explor. 2020;2(9):e0192. doi:10.1097/CCE.0000000000000192
81.
MortusJRManekSEBrubakerLS, et al.Thromboelastographic results and hypercoagulability syndrome in patients with coronavirus disease 2019 who are critically ill. JAMA Netw Open. 2020;3(6):e2011192. doi:10.1001/jamanetworkopen.2020.11192
82.
HelmsJTacquardCSeveracF, et al.High risk of thrombosis in patients in severe SARS-CoV-2 infection: a multi-center prospective cohort study. Intensive Care Med. 2020;46(6):1089–1098. doi:10.1007/s00134-020-06062-x
83.
LlitjosJFLeclercMChochoisC, et al.High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J Thromb Haemost. 2020:1–4. doi:10.1111/jth.14869
84.
LimWMeadeMLauzierF, et al.Failure of anticoagulant thromboprophylaxis: risk factors in medical-surgical critically ill patients. Crit Care Med. 2015;43(2):401–410. doi:10.1097/CCM.0000000000000713
85.
MiddeldorpSCoppensMvan HaapsTF, et al.Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost.2020;18(8):1995–2002. doi:10.1111/jth.14888
86.
ThomasWVarleyJJohnstonA, et al.Thrombotic complications of patients admitted to intensive care with COVID-19 at a teaching hospital in the United Kingdom. Thromb Res. 2020;191:76–77. doi:10.1016/j.thromres.2020.04.028
87.
LodigianiCIapichinoGCarenzoL, et al.Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res. 2020;191:9–14. doi:10.1016/j.thromres.2020.04.024
88.
CattaneoMBertinatoEMBirocchiS, et al.Pulmonary embolism or pulmonary thrombosis in COVID-19? Is the recommendation to use high-dose heparin for thromboprophylaxis justified?Thromb Haemost. 2020;120(8):1230–1232. doi:10.1055/s-0040-1712097 C
89.
ShiLXuJDuanGYangHWangY.The pooled prevalence of pulmonary embolism in patients with COVID-19[published online September 14, 2020]. Intensive Care Med. 2020:1–3. doi:10.1007/s00134-020-06235-8
90.
WichmannDSperhakeJPLütgehetmannM, et al.Autopsy findings and venous thromboembolism in patients with COVID-19. Ann Intern Med. 2020;173(4). doi:10.7326/m20-2003
91.
AckermannMVerledenSEKuehnelM, et al.Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in COVID-19. N Engl J Med. 2020;383(2):120–128. doi:10.1056/NEJMoa2015432
92.
RapkiewiczAVMaiXCarsonsSE, et al.Thrombosis at autopsy in COVID-19: a case series. E Clin Med. 2020;24:100434.
93.
BryceCGrimesZPujadasE, et al.Pathophysiology of SARS-CoV-2: targeting of endothelial cells renders a complex disease with thrombotic microangiopathy and aberrant immune response. The Mount Sinai COVID-19 autopsy experience[published online May 22, 2020]. Medrxiv. 2020. doi:10.1101/2020.05.18.20099960
94.
FridmanSBullrichMBJimenez-RuizA, et al.Stroke risk, phenotypes, and death in COVID-19: systematic review and newly reported cases[published online September 15, 2020]. Neurology. 2020. doi:10.1212/WNL.0000000000010851
95.
TangNBaiHChenXGongJLiDSunZ.Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18(5):1094–1099. doi:10.1111/jth.14817
96.
ParanjpeIFusterVLalaA, et al.Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19. J Am Coll Cardiol. 2020;76(1):122–124. doi:10.1016/j.jacc.2020.05.001
97.
TacconeFSGevenoisPAPelusoL, et al.Higher intensity thromboprophylaxis regimens and pulmonary embolism in critically ill coronavirus disease 2019 patients. Crit Care Med.2020;48(11):e1087–e1090. doi:10.1097/ccm.0000000000004548
MandalAKDamPFrancoOL, et al.Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and mandarin on the novel coronavirus COVID-19. Ann Oncol. 2020:19–21. doi:10.1007/s00134-020-05991-x.Bizzarro
100.
JonmarkerSHollenbergJDahlbergM, et al.Dosing of thromboprophylaxis and mortality in critically ill Covid-19 patients authors[published online September 23, 2020]. Medrxiv. 2020. doi:10.1101/2020.09.17.20195867
101.
LemosACBdo Espírito SantoDASalvettiMC, et al.Therapeutic versus prophylactic anticoagulation for severe COVID-19: a randomized phase II clinical trial (HESACOVID). Thromb Res. 2020;196(September):359–366. doi:10.1016/j.thromres.2020.09.026
102.
KlokFAKruipMJHAvan der MeerNJM, et al.Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis. Thromb Res. 2020;191(April):148–150. doi:10.1016/j.thromres.2020.04.041
103.
MaierCLTruongADAuldSCPollyDMTanksleyCLDuncanA.COVID-19-associated hyperviscosity: a link between inflammation and thrombophilia? Lancet. 2020;395(10239):1758–1759. doi:10.1016/S0140-6736(20)31209-5
104.
KhamisFAl-ZakwaniIAl HashmiS, et al.Therapeutic plasma exchange in adults with severe COVID-19 infection. Int J Infect Dis. 2020;99:214–218. doi:10.1016/j.ijid.2020.06.064
105.
LimSYJeonKKimHJ, et al.Antifactor Xa levels in critically ill Korean patients receiving enoxaparin for thromboprophylaxis: a prospective observational study. J Korean Med Sci. 2013;28(3):466–471. doi:10.3346/jkms.2013.28.3.466
106.
WhiteDMacDonaldSBullT, et al.Heparin resistance in COVID-19 patients in the intensive care unit. J Thromb Thrombolysis. 2020;50(2):287–291. doi:10.1007/s11239-020-02145-0
107.
Tomasa-IrriguibleTMMartínez-VegaSMor-MarcoEHerraiz-RuizARaguer-PardoLCubells-LarrosaC.Low molecular weight heparins in COVID-19 patients: beware of augmented renal clearance!Crit Care. 2020;24(1):4–5. doi:10.1186/s13054-020-03058-3
108.
BiancatelliRMLCBerrillMMohammedYHMarikPE. Melatonin for the treatment of sepsis: The scientific rationale. J Thorac Dis. 2020;2(Suppl 1):S54–S65. doi:10.21037/jtd.2019.12.85
109.
LiuJCloughSJHutchinsonAJAdamah-BiassiEBPopovska-GorevskiMDubocovichML. MT 1 and MT 2 melatonin receptors: a therapeutic perspective. Annu Rev Pharmacol Toxicol. 2016;56:361–383. doi:10.1146/annurev-pharmtox-010814-124742
110.
Carrillo-VicoAReiterRJLardonePJ, et al.The modulatory role of melatonin on immune responsiveness. Curr Opin Investig Drugs. 2006;7(5):423–431.
111.
EspinoJParienteJARodríguezAB. Oxidative stress and immunosenescence: therapeutic effects of melatonin. Oxid Med Cell Longev. 2012;2012:670294. doi:10.1155/2012/670294
112.
Dominguez-RodriguezAAbreu-GonzalezPMarikPEReiterRJ. Melatonin, cardiovascular disease and COVID-19: a potential therapeutic strategy?Melatonin Res. 2020;3:318–321.
113.
ReiterRJSharmaRMaQDominquez-RodriguezAMarikPEAbreu-GonzalezP. Melatonin inhibits COVID-19-induced cytokine storm by reversing aerobic glycolysis in immune cells: a mechanistic analysis. Med Drug Discov. 2020;6:100044. doi:10.1016/j.medidd.2020.100044
114.
ReiterRJAbreu-GonzalezPMarikPEDominguez-RodriguezA.Therapeutic algorithm for use of melatonin in patients with COVID-19. Front Med. 2020;7:226. doi:10.3389/fmed.2020.00226
115.
ZhouYHouYShenJHuangYMartinWChengF.Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. Cell Discov. 2020;6(1):1–8. doi:10.1038/s41421-020-0153-3
ZhangRWangXNiL, et al.COVID-19: melatonin as a potential adjuvant treatment. Life Sci. 2020;250:115783. doi:10.1016/j.lfs.2020.117583
118.
AldhousMFraneyCWrightJArendtJ. Plasma concentrations of melatonin in man following oral absorption of different preparations. Br J Clin Pharmacol. 1985;19(4):517–521doi:10.1111/j.1365-2125.1985.tb02679.x
119.
SkalnyAVRinkLAjsuvakovaOP, et al.Zinc and respiratory tract infections: perspectives for COVID’19 (Review). Int J Mol Med. 2020;46(1):17–26. doi:10.3892/ijmm.2020.4575
120.
GammohNZRinkL. Zinc in infection and inflammation. Nutrients. 2017;9(6):624. doi:10.3390/nu9060624
121.
HeylandDKJonesNCvijanovichNZWongH. Review: Zinc supplementation in critically ill patients: a key pharmaconutrient?J Parenter Enter Nutr. 2008;32(5):509–519. doi:10.1177/0148607108322402
122.
LimSSVosTFlaxmanAD, et al.A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380(9859):2224–2260. doi:10.1016/S0140-6736(12)61766-8
123.
BhuttaZAAhmedTBlackRE, et al.What works? Interventions for maternal and child undernutrition and survival. Lancet. 2008;371(9610):517–540. doi:10.1016/S0140-6736(07)61693-6
124.
MagginiSWenzlaffSHornigD.Essential role of vitamin C and zinc in child immunity and health. J Int Med Res. 2010;38(2):386–414. doi:10.1177/147323001003800203
125.
LinkoRKarlssonSPettilãV, et al.Serum zinc in critically ill adult patients with acute respiratory failure. Acta Anaesthesiol Scand. 2011;55(5):615–621. doi:10.1111/j.1399-6576.2011.02425.x
126.
MertensKLowesDAWebsterNR, et al.Low zinc and selenium concentrations in sepsis are associated with oxidative damage and inflammation. Br J Anaesth. 2015;114(6):990–999. doi:10.1093/bja/aev073
BoudreaultFPinilla-VeraMEnglertJA, et al.Zinc deficiency primes the lung for ventilator-induced injury. JCI insight. 2017;2(11):e865707. doi:10.1172/jci.insight.86507
129.
SinghMDasRR. Zinc for the common cold. Evidence-Based Child Heal. 2012;7(4):1235–1308doi:10.1002/ebch.1859
130.
HemiläH. Zinc lozenges and the common cold: a meta-analysis comparing zinc acetate and zinc gluconate, and the role of zinc dosage. JRSM Open. 2017;8(5):1–7. doi:10.1177/2054270417694291
131.
MeydaniSNBarnettJBDallalGE, et al.Serum zinc and pneumonia in nursing home elderly. Am J Clin Nutr. 2007;86(4):1167–1173. doi:10.1093/ajcn/86.4.1167
132.
Te VelthuisAJWvan den WormlSHESimsACBaricRSSnijderEJvan HemertMJ. Zn2+ inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture. PLoS Pathog. 2010;6(11):e1001176. doi:10.1371/journal.ppat.1001176
133.
XueJMoyerAPengBWuJHannafonBNDingWQ. Chloroquine is a zinc ionophore. PLoS One. 2014;9(10):e109180. doi:10.1371/journal.pone.0109180
134.
Dabbagh-BazarbachiHClergeaudGQuesadaIMOrtizMO’SullivanCKFernández-LarreaJB.Zinc ionophore activity of quercetin and epigallocatechin-gallate: from HEPA 1-6 cells to a liposome model. J Agric Food Chem. 2014;62(32):8085–8093. doi:10.1021/jf5014633
135.
ShittuMOAfolamiOI.Improving the efficacy of chloroquine and hydroxychloroquine against SARS-CoV-2 may require zinc additives—a better synergy for future COVID-19 clinical trials. Le Infez Med. 2020;28(2):192–197.
136.
RondanelliMMicconoALamburghiniS, et al.Self-care for common colds: the pivotal role of vitamin D, vitamin C, zinc, and echinacea in three main immune interactive clusters (physical barriers, innate and adaptive immunity) involved during an episode of common colds—practical advice on dosages. Evid based Complement Alternat Med. 2018;583095. doi:10.1155/2018/5813095
137.
HuangCWangYLiX, et al.Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. doi:10.1016/S0140-6736(20)30183-5
138.
SharifiAVahediHNedjatSRafieiHHosseinzadeh-AttarMJ. Effect of single-dose injection of vitamin D on immune cytokines in ulcerative colitis patients: a randomized placebo-controlled trial. APMIS. 2019;127(10):681–687. doi:10.1111/apm.12982
GrantWBLahoreHMcDonnellSL, et al.Evidence that vitamin D supplementation could reduce risk of influenza and Covid-19 infections and deaths. Nutrients. 2020;12(4):1–19. doi:10.3390/nu12040988
141.
QuraishiSABittnerEABlumLHutterMMCamargoCA.Association between preoperative 25-hydroxyvitamin D level and hospital-acquired infections following roux-en-Y gastric bypass surgery. JAMA Surg. 2014;149(2):112–118.
142.
CannellJJViethRUmhauJC, et al.Epidemic influenza and vitamin D. Epidemiol Infect. 2006;134(6):1129–1140. doi:10.1017/S0950268806007175
143.
YoussefDARanasingheTGrantWBPeirisAN. Vitamin D’s potential to reduce the risk of hospital-acquired infections. Dermatoendocrinol. 2012;4(2):167–175doi:10.4161/derm.20789
144.
RhodesJMSubramanianSLairdEKennyRA. Letter: Low population mortality from COVID-19 in countries south of latitude 35° North supports vitamin D as a factor determining severity. Authors’ reply. Aliment Pharmacol Ther. 2020;52(2):412–413. doi:10.1111/apt.15823
145.
KaufmanHWNilesJKKrollMHBiCHolickMF.SARS-CoV-2 positivity rates associated with circulating 25-hydroxyvitamin D levels. PLoS One. 2020;15(9):e0239252. doi:10.1371/journal.pone.0239252
146.
MartineauARJolliffeDAHooperRL, et al.A vitamin D supplementation to prevent acute respiratory tract infections. BMJ. 2017;356:i6583. doi:10.1136/bmj.i6583
147.
KafanSTabrizHMHadadiAMontazeriMNasiriM. Vitamin D sufficiency, a serum 25- hydroxyvitamin D at least 30 ng/mL reduced risk for adverse clinical outcomes in patients with COVID-19 infection. 2020;15(9):1–13. doi:10.1371/journal.pone.0239799
148.
VenkateshBNairP.Hypovitaminosis D and morbidity in critical illness: is there proof beyond reasonable doubt?Crit Care. 2014;18(3):7–9. doi:10.1186/cc13863
149.
LeePEismanJACenterJR. Vitamin D deficiency in critically ill patients. N Engl J Med. 2009;350:1912–1914. doi:10.1056/NEJMc0809996
150.
ZhangYPWanYDSunTWKanQCWangLX. Association between vitamin D deficiency and mortality in critically ill adult patients: a meta-analysis of cohort studies. Crit Care. 2014;18(6):1–8. doi:10.1186/s13054-014-0684-9
151.
AmreinKZajicPSchnedlC, et al.Vitamin D status and its association with season, hospital and sepsis mortality in critical illness. Crit Care. 2014;18(2):R47. doi:10.1186/cc13790
152.
PutzuABellettiACassinaT, et al.Vitamin D and outcomes in adult critically ill patients. A systematic review and meta-analysis of randomized trials. J Crit Care.2017;38:109–114. doi:10.1016/j.jcrc.2016.10.029
153.
AmreinKMartucciGMcNallyJD.When not to use meta-analysis: analysing the meta-analyses on vitamin D in critical care. Clin Nutr. 2017;36(6):1729–1730. doi:10.1016/j.clnu.2017.08.009
154.
GindeAABrowerRGCaterinoJM, et al.Early high-dose vitamin D3 for critically ill, vitamin D–deficient patients. N Engl J Med. 2019;381(26):2529–2540. doi:10.1056/NEJMoa1911124
155.
BarabutisNKhangooraVMarikPECatravasJD. Hydrocortisone and ascorbic acid synergistically prevent and repair lipopolysaccharide-induced pulmonary endothelial barrier dysfunction. Chest. 2017;152(5):954–962. doi:10.1016/j.chest.2017.07.014
156.
KuhbandnerKHammerAHaaseS, et al.Mucosal addressin cell adhesion molecule 1 mediated intestinal lymphocyte homing is critical for the development of experimental autoimmune encephalomyelitis. Mult Scler J. 2018;24:(s2):8–120.
157.
ZhangYLeungDYMGolevaE.Vitamin D enhances glucocorticoid action in human monocytes: involvement of granulocyte-macrophage colony-stimulating factor and mediator complex subunit 14. J Biol Chem. 2013;288(20):14544–14553. doi:10.1074/jbc.M112.427054
158.
ZhangYLeungDYMGolevaE.Anti-inflammatory and corticosteroid-enhancing actions of vitamin D in monocytes of patients with steroid-resistant and those with steroid-sensitive asthma. J Allergy Clin Immunol. 2014;133(6):1744–1752.e1. doi:10.1016/j.jaci.2013.12.004
159.
ChristopherKB. Vitamin D supplementation in the ICU patient. Curr Opin Clin Nutr Metab Care. 2015;18(2):187–1902. doi:10.1097/MCO.0000000000000147
160.
BergmanP. The link between vitamin D and Covid-19: distinguishing facts from fiction[published online ahead of print July 11, 2020]. J Intern Med. doi:10.1111/joim.13158
161.
HanJEJonesJLTangprichaV, et al.High dose vitamin D administration in ventilated intensive care unit patients: a pilot double blind randomized controlled trial. J Clin Transl Endocrinol. 2016;4:59–65. doi:10.1016/j.jcte.2016.04.004
162.
AmreinKSchnedlCBergholdAPieberTRDobniH. Correction of vitamin D deficiency in critically ill patients: a randomized placebo-controlled trial. Clin Nutr. 2014;33:S13. doi:10.1016/S0261-5614(14)50030-1
163.
WanYDSunTWKanQCGuanFXZhangSG.Effect of statin therapy on mortality from infection and sepsis: a meta-analysis of randomized and observational studies. Crit Care. 2014;18(2):1–13. doi:10.1186/cc13828
164.
PertzovBEliakim-RazNAtamnaHTrestioreanuAZYahavDLeiboviciL. Hydroxymethylglutaryl-CoA reductase inhibitors (statins) for the treatment of sepsis in adults—a systematic review and meta-analysis. Clin Microbiol Infect. 2019;25(3):280–289. doi:10.1016/j.cmi.2018.11.003
165.
GaoXQLiYFJiangZL.Impact of statins on ALI/ARDS: a meta-analysis. Pulm Pharmacol Ther. 2016;39:85–91. doi:10.1016/j.pupt.2016.06.010
166.
KrugerPBaileyMBellomoR, et al.A multicenter randomized trial of atorvastatin therapy in intensive care patients with severe sepsis. Am J Respir Crit Care Med. 2013;187(7):743–750. doi:10.1164/rccm.201209-1718OC
167.
KrugerPSTerblancheM. Statins in patients with sepsis and ARDS: is it over? No. Intensive Care Med. 2017;43(5):675–676. doi:10.1007/s00134-016-4564-4
168.
McAuleyDFLaffeyJGO’KaneCM, et al.Simvastatin in the acute respiratory distress syndrome. N Engl J Med. 2014;371(18):1695–1703. doi:10.1056/NEJMoa1403285
169.
CalfeeCSDelucchiKLSinhaP, et al.Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial. Lancet Respir Med. 2018;6(9):691–698. doi:10.1016/S2213-2600(18)30177-2
170.
Rodriguez-NavaGTrelles-GarciaDPYanez-BelloMAChungCWTrelles-GarciaVPFriedmanHJ. Atorvastatin associated with decreased hazard for death in COVID-19 patients admitted to an ICU: a retrospective cohort study. Crit Care. 2020;24(1):429. doi:10.1186/s13054-020-03154-4
171.
JafarzadehANematiMKhorramdelazadHHassanZM.Immunomodulatory properties of cimetidine: its therapeutic potentials for treatment of immune-related diseases. Int Immunopharmacol. 2019;70:156–166doi:10.1016/j.intimp.2019.02.026.
172.
SmolinskaSGroegerDPerezNR, et al.Histamine receptor 2 is required to suppress innate immune responses to bacterial ligands in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2016;22(6):1442–1449doi:10.1097/MIB.0000000000000825
173.
MorichikaTTakahashiHKIwagakiH, et al.Histamine inhibits lipopolysaccharide-induced tumor necrosis factor-α production in an intercellular adhesion molecule-1- and B7.1-dependent manner. J Pharmacol Exp Ther. 2003;304(2):624–633. doi:10.1124/jpet.102.042515
174.
BourinbaiarASFruhstorferEC. The effect of histamine type 2 receptor antagonists on human immunodeficiency virus (HIV) replication: identification of a new class of antiviral agents. Life Sci. 1996;59(23):PL365–P370. doi:10.1016/s0024-3205(96)00553-x
175.
GoldsteinJA. Cimetidine, ranitidine, and Epstein-Barr virus infection. Ann Intern Med. 1986;105(1):139. doi:10.7326/0003-4819-105-1-139_2
176.
GooptuCHigginsCRJamesMP. Treatment of viral warts with cimetidine: an open-label study. Clin Exp Dermatol. 2000;25(3):183–185. doi:10.1046/j.1365-2230.2000.00608.x
177.
YangNTannerJAZhengBJ, et al.Bismuth complexes inhibit the SARS coronavirus. Angew Chemie—Int Ed. 2007;46(34):6464–6468. doi:10.1002/anie.200701021
178.
FreedbergDEConigliaroJWangTC, et al.Famotidine use is associated with improved clinical outcomes in hospitalized COVID-19 patients: a propensity score matched retrospective cohort study[published online ahead of print May 22, 2020]. Gastroenterology. 2020. doi:10.1053/j.gastro.2020.05.053
179.
TobinMJLaghiFJubranA. Why COVID-19 silent hypoxemia is baffling to physicians. Am J Respir Crit Care Med. 2020;202(3):356–360. doi:10.1164/rccm.202006-2157cp
180.
Couzin-FrankelJ. The mystery of the pandemic’s happy hypoxia. Science. 2020;368(6490):455–456. doi:10.1126/science.368.6490.455
181.
CobesNGuernouMLussatoD, et al.Ventilation /perfusion SPECT/CT findings in different lung lesions associated with COVID-19: a case series. Eur J Nuclear Med Mol Imag. 2020;47(10):2453–2460. doi:/10.1007/s00259-020-04920-w
182.
PatelB VArachchillageDJRidgeCA, et al.Pulmonary angiopathy in severe Covid-19: physiologic, imaging, and hematologic observations. 2020;202(5):690–699. doi:10.1164/rccm.202004-1412OC
183.
MarikPEVaronJKoryP.Treatment of COVID-19 is critically phase specific. Crit Care Shock. 2020;23(5):10–12.
184.
KeithPDayMPerkinsLMoyerLHewittKWellsA. A novel treatment approach to the novel coronavirus: an argument for the use of therapeutic plasma exchange for fulminant COVID-19. Crit Care. 2020;24(1):1–3. doi:10.1186/s13054-020-2836-4
185.
FernandezJGratacos-GinèsJOlivasP, et al.Plasma exchange: an effective rescue therapy in critically ill patients with coronavirus disease 2019 infection. Crit Care Med. 2020;(9):1–6. doi:10.1097/CCM.0000000000004613
186.
AdeliSHAsghariATabarraiiR, et al.Therapeutic plasma exchange as a rescue therapy in patients with coronavirus disease 2019: a case series. Polish Arch Intern Med. 2020;130(5):455–458. doi:10.20452/pamw.15340
187.
VardanjaniERoncoCRafieiHGolitalebMPishvaeiMHMohammadiM.Early hemoperfusion for cytokine removal may contribute to prevention of intubation in patients infected with COVID-19[published online June 26, 2020]. Blood Purif. 2020:1–4. doi:10.1159/000509107
188.
AltmayerVSahebSRohautB, et al.Therapeutic plasma exchange in a critically ill Covid-19 patient. J Clin Apher. 2020;(June):4–7. doi:10.1002/jca.21830
189.
AkkoyunluYCetinGBolukcuSDurduBOkyaltirikFKaraaslanK. The successful management of an elderly Covid-19 infected patient by plasmapheresis[published online August 25, 2020]. Transfus Apher Sci. 2020. doi:10.1016/j.transci.2020.102924
190.
FaqihiFAlharthyAAlodatMKutsogiannisDJBrindleyPGKarakitsosD. Therapeutic plasma exchange in adult critically ill patients with life-threatening SARS-CoV-2 disease: a pilot study[published online July 31, 2020]. J Crit Care. 2020:1–6. doi:10.1016/j.jcrc.2020.07.001
191.
TianHSuiYTianS, et al.Case report: clinical treatment of the first critical patient with coronavirus disease (COVID-19) in Liaocheng, Shandong province. Front Med. 2020;7. doi:10.3389/fmed.2020.00249
ZhangLZhaiHMaSChenJGaoY. Efficacy of therapeutic plasma exchange in severe COVID-19 patients. Br J Haematol. 2020;190(4):e181–e183. doi:10.1111/bjh.16890
194.
ShiHZhouCHeP, et al.Successful treatment with plasma exchange followed by intravenous immunoglobulin in a critically ill patient with COVID-19. Int J Antimicrob Agents. 2020;56(2):105974. doi:10.1016/j.ijantimicag.2020.105974
195.
DePaceNLSolowaySRoshalDSolowayAMColomboJ. Unexpected SARS-CoV-2 cardiorespiratory arrest in a myopathy patient undergoing immunosuppressive treatment: a case report. Medicine (Baltimore). 2020;99(30):e21377. doi:10.1097/MD.0000000000021377
196.
GucyetmezBAtalanHKSertdemirISertdemirICakirUTelciL. Therapeutic plasma exchange in patients with COVID-19 pneumonia in intensive care unit: a retrospective study. Crit Care. 2020;24(1):4–7. doi:10.1186/s13054-020-03215-8
197.
KamranSMMirzaZHNaseemA, et al.PLEXIT—therapeutic plasma exchange (TPE) for Covid-19 cytokine release storm (CRS), a retrospective propensity matched control study[published online July 29, 2020]. medRxiv. 2020. doi:10.1101/2020.07.23.20160796
